1354 related articles for article (PubMed ID: 18782778)
1. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
2. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
3. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
5. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
6. Azole resistance of Candida glabrata in a case of recurrent fungemia.
Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G
J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
10. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
[TBL] [Abstract][Full Text] [Related]
11. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the CgPDR1 and CgERG11 genes in azole-resistant Candida glabrata clinical isolates from Slovakia.
Berila N; Borecka S; Dzugasova V; Bojnansky J; Subik J
Int J Antimicrob Agents; 2009 Jun; 33(6):574-8. PubMed ID: 19196495
[TBL] [Abstract][Full Text] [Related]
15. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
16. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
[TBL] [Abstract][Full Text] [Related]
17. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
[TBL] [Abstract][Full Text] [Related]
18. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.
Lee I; Zaoutis TE; Fishman NO; Morales KH; Nachamkin I; Lautenbach E
Am J Infect Control; 2010 Aug; 38(6):456-60. PubMed ID: 20371135
[TBL] [Abstract][Full Text] [Related]
20. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility.
Arendrup MC; Fuursted K; Gahrn-Hansen B; Schønheyder HC; Knudsen JD; Jensen IM; Bruun B; Christensen JJ; Johansen HK
Clin Microbiol Infect; 2008 May; 14(5):487-94. PubMed ID: 18294241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
